PRDM5: A Potential Drug Target Or Biomarker (G11107)

Target Name: PRDM5

NCBI ID: G11107

PRDM5

PRDM5: A Potential Drug Target Or Biomarker

PRDM5, also known as PRDM5-AS1, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. PRDM5 is a non-coding RNA molecule that is expressed in various tissues and cells in the body. It is a key regulator of gene expression and has been shown to play a role in the development and progression of many diseases.

One of the key features of PRDM5 is its ability to interact with a variety of transcription factors, including activator proteins that can cause gene expression to increase. This interaction between PRDM5 and transcription factors makes it a potential target for drugs that aim to reduce gene expression or inhibit the activity of transcription factors.

PRDM5 has been shown to be involved in the regulation of many different genes, including those involved in cell growth, differentiation, and apoptosis. It has been shown to play a role in the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key ways in which PRDM5 is involved in these diseases is by regulating the activity of immune cells, including T cells and natural killer cells. These cells play a critical role in protecting the body against infection and disease, and their activity is often disrupted in diseases such as cancer and autoimmune disorders.

PRDM5 has also been shown to be involved in the regulation of cell death, which is a critical process that helps maintain the integrity of tissues and organs. Cell death is regulated by a complex network of factors, including the activity of transcription factors, and PRDM5 is thought to play a role in this process.

In addition to its involvement in disease regulation, PRDM5 is also of interest as a potential drug target. By inhibiting the activity of PRDM5, drugs can reduce the production of gene expression that is associated with disease, including cancer cells, neurodegenerative diseases, and autoimmune disorders. This can lead to a reduction in the severity and progression of these diseases.

PRDM5 is also of interest as a potential biomarker for disease. By measuring the expression of PRDM5, researchers can gain insights into the activity of different genes and their role in disease. This can help identify new targets for drugs and other therapies that aim to treat disease.

Overall, PRDM5 is a gene that has significant potential as a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in disease regulation and its potential as a therapeutic approach.

Protein Name: PR/SET Domain 5

Functions: Sequence-specific DNA-binding transcription factor. Represses transcription at least in part by recruitment of the histone methyltransferase EHMT2/G9A and histone deacetylases such as HDAC1. Regulates hematopoiesis-associated protein-coding and microRNA (miRNA) genes. May regulate the expression of proteins involved in extracellular matrix development and maintenance, including fibrillar collagens, such as COL4A1 and COL11A1, connective tissue components, such as HAPLN1, and molecules regulating cell migration and adhesion, including EDIL3 and TGFB2. May cause G2/M arrest and apoptosis in cancer cells

The "PRDM5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRDM5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets